

Neurotech secures Notices of Allowance for two U.S. patent applications

Highlights

- The USPTO has sent Notices of Allowance for two NTI patent applications.
- Granting of these two U.S. patents is expected within the coming months.
- Once granted, the patents will provide intellectual property protection for NTI164 through to 2042.

Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce that the United States Patent and Trademark Office (**USPTO**) has sent Notices of Allowance for U.S. patent applications No. 18/698,605 and No. 19/335,945. These applications relate to key aspects of the Company’s NTI164 product and are both titled “Compositions and Methods for Treating Neurological Disorders”.

The allowed claims of U.S. Patent Application No. 18/698,605 cover methods of reducing neuroinflammation using NTI164 and the allowed claims of U.S. Patent Application No. 19/335,945 are specifically directed to methods of treating autism spectrum disorder (**ASD**).

Once granted, these patents are expected to further strengthen Neurotech’s intellectual property portfolio for NTI164, which is currently in Phase 3 clinical development for the treatment of ASD in paediatric patients. The patents will not be enforceable until formally granted. The Notices of Allowance confirm that the USPTO has determined the applications meet the requirements for patentability and issuance of two U.S. patents is expected within the coming months, subject to completion of standard administrative processes. Subject to the payment of applicable maintenance fees, these patents are expected to provide intellectual property protection for NTI164 through to 2042.

Anthony Filippis, CEO and Managing Director, commented:

“These Notices of Allowance represent further execution of our strategy to create value by protecting our assets and expanding our global IP portfolio.

The USPTO’s determination that both applications satisfy the requirements for patentability is an important step in the progression of the Company’s US intellectual property strategy for NTI164.

As we enter the new financial year, we remain focused on achieving key milestones for NTI164 to address the urgent need for effective treatments for children diagnosed with ASD.”

Authority

This announcement was authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

For personal use only